ea0077lb22 | Late Breaking | SFEBES2021
Abouzaid Mona
, Holliday Rachel
, Boot Chris
, Quinton Richard
, Mamoojee Yaasir
Background: Enzalutamide is a next-generation androgen receptor (AR) antagonist, used as a daily oral agent, in the treatment of castration-resistant prostate cancer. Its suppression of 11β-hydroxysteroid dehydrogenase-2 enzyme has been reported in the literature, leading to hypertension through a relative increase in cortisol concentration at the level of the mineralocorticoid receptors. Enzalutamide is also known to be a potent inducer of drug metabolising enzymes (cyto...